Action STOK STOKE THERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Stoke Therapeutics, Inc.

Actions

STOK

US86150R1077

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 17/07/2024 		Varia. 5j. Varia. 1 janv.
13,68 USD -7,19 % Graphique intraday de Stoke Therapeutics, Inc. +3,17 % +160,08 %
21/06 Le Dr Huw Nash quitte son poste de directeur des opérations de Stoke Therapeutics, Inc. CI
13/06 Stoke Therapeutics dépose une déclaration d'enregistrement pour la vente de 10,8 millions d'actions par les actionnaires MT

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BU
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BU
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
BU
Encephalopathy Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)
AQ
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BU
Stoke Therapeutics : Corporate Presentation - May 2024
PU
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
BU
Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer
BU
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
BU
Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
BU
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
BU
Stoke Therapeutics Announces Proposed Public Offering
BU
Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
BU
Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome
BU
Scion Life Sciences Launches with Oversubscribed $310 Million Fund to Create and Build Exceptional Biotech Companies
AQ
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BU
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action STOK
  4. Actualités Stoke Therapeutics, Inc.
  5. Communiqués